BASEL, Switzerland, October 29, 2012 /PRNewswire/ --

Swiss based Citys AG has arranged a distribution agreement for the Republic of Iran for BioAlliance Pharma SA, a company dedicated to the development of orphan oncology drugs and supportive care products headquartered in Paris. The agreement covers BioAlliance´s Loramyc^® drug, a miconazole Lauriad™ mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients.

"For BioAlliance the agreement concluded through Cytis AG marks the expansion of Loramyc^®'s commercialization worldwide, and especially to emergent markets," declares Judith Greciet, CEO of BioAlliance Pharma.

Distributor in Iran will be Shafayab Gostar, a company established in 2001. The agreement will bring an innovative product to Iran that meets a medical need in a market where some 180,000 new cancer cases are diagnosed every year. Loramyc^® provides a new therapeutic solution to patients suffering from oropharyngeal candidiasis, improves their care, particularly for patients at risk, and their quality of life.

About Cytis AG

Cytis AG (http://www.cytis.ch) is dedicated to the commercialization and promotion in the fields of biopharmaceuticals, pharmaceuticals, medical equipments and diagnostics via partnerships, distribution setups or licensing, especially in emerging markets and more specifically in Middle East and Central Europe. This activity contributes to fulfill unmet medical needs of patients and develop geographical expansion of innovative companies.

About BioAlliance Pharma SA

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

Further Information :
Patrick Durand
Cytis AG
Gewerbestrasse 14
4123 Allschwil, Switzerland
P: +41(0)61-481-6611
M: welcome@cytis.ch

Media Inquiries:
Ulrich L. Schneppel
York Communications GmbH
Henric Petri-Strasse 6
4051 Basel, Switzerland
P: +41(0)61-508-2917
M: cytis@york-communications.ch

SOURCE Cytis AG